Reduction of proteinuria by rosiglitazone in non-diabetic renal disease

Nephrology (Carlton). 2008 Feb;13(1):58-62. doi: 10.1111/j.1440-1797.2007.00903.x.

Abstract

Aim: To investigate the effect of a thiazolidinedione on proteinuria in patients with non-diabetic renal disease.

Methods: In an open-label randomized cross-over study, 40 adults with chronic non-diabetic renal disease completed the study. In a random fashion, one group was treated for 4 months with 4 mg of rosiglitazone first followed by a 4-month period of standard treatment. The opposite order was used for the second group.

Results: Baseline urinary protein excretion rate was 1.45 g/24 h. On rosiglitazone, there was a drop of urinary protein level of 0.24 g/24 h (P=0.045). In contrast, there was a trend for proteinuria to increase during the control period (0.12 g/24 h, P=0.18). The urine protein level on rosiglitazone was lower than on usual treatment (0.36 g/24 h, P=0.002, 95% CI 0.15-0.58). There was a similar beneficial effect on systolic blood pressure which was reduced by rosiglitazone by 7.8 mmHg (P=0.006, 95% CI 2.6-13.1). Although average fasting glucose was only 5.8 mmol/L, there was a significant Spearman correlation between fasting glucose and a reduction in urinary protein levels (r=0.34, P=0.045).

Conclusion: It is concluded that thiazolidinediones may have a role in the management of non-diabetic proteinuria of various aetiologies. In this study the average body mass index was 28.9 kg/m2. It will be important to repeat these studies in non-overweight subjects with non-diabetic proteinuria and in addition to trial maximal therapeutic doses of the thiazolidenedione.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Biomarkers / urine
  • Blood Glucose / metabolism
  • Body Mass Index
  • Cross-Over Studies
  • Diabetes Mellitus
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / blood
  • Male
  • Middle Aged
  • Obesity / complications*
  • Obesity / metabolism
  • PPAR gamma
  • Proteinuria / drug therapy*
  • Proteinuria / etiology
  • Proteinuria / metabolism
  • Retrospective Studies
  • Rosiglitazone
  • Thiazolidinediones / administration & dosage
  • Thiazolidinediones / therapeutic use*
  • Treatment Outcome

Substances

  • Biomarkers
  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • PPAR gamma
  • Thiazolidinediones
  • Rosiglitazone